CYP2C8 and ovarian carcinoma: In large cohorts of patients with ovarian cancer treated with carboplatin and either paclitaxel or docetaxel, CYP2C8 gene polymorphisms had no impact on patient outcome and chemotherapy-induced toxicity [51].